BACKGROUND: The characterization of the first episode of @entity716 and how it should be treated are principal issues in actual research. Realistic, naturalistic studies are necessary to represent the entire population of first episode of @entity716 attended in daily practice. METHODS: Sixteen participating centers from the @entity34186 project recruited 335 first episode of @entity716 @entity1 , aged 7 to 35 years. This article describes and discusses the psychopharmacological interventions and safety profiles at baseline and during a 60-day pharmacovigilance period. RESULTS: The majority of first episode of @entity716 @entity1 received a second-generation antipsychotic (96.3%), orally (95%), and in adjusted doses according to the product specifications (87.2%). A total of 24% were receiving an antipsychotic polytherapy pattern at baseline, frequently associated with lower or higher doses of antipsychotics than the recommended ones. Eight @entity1 were taking @entity1088 , all in monotherapy. Males received higher doses of antipsychotic (P=.043). A total of 5.2% of the @entity1 were being treated with long-acting injectable antipsychotics; 12.2% of the patients received anticholinergic drugs, 12.2% antidepressants, and 13.7% mood stabilizers, while almost 40% received @entity1245 ; and 35.52% reported at least one adverse drug reaction during the pharmacovigilance period, more frequently associated with higher antipsychotic doses and antipsychotic polytherapy (85.2% vs 45.5%, P<.001). CONCLUSIONS: These data indicate that the overall pharmacologic prescription for treating a first episode of @entity716 in Spain follows the clinical practice guideline recommendations, and, together with security issues, support future research of determinate pharmacological strategies for the treatment of early phases of @entity716 , such as the role of @entity1088 , long-acting injectable antipsychotics, antipsychotic combination, and the use of @entity1245 .

A Pharmacovigilance Study in First Episode of Psychosis: Psychopharmacological Interventions and Safety Profiles in the XXXX Project.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity1088 :: ('MESH:D003024', 'Chemical') :: ['clozapine'] @entity1245 :: ('MESH:D001569', 'Chemical') :: ['benzodiazepines'] @entity716 :: ('MESH:D011605', 'Disease') :: ['psychosis'] @entity34186 :: ('51056', 'Gene') :: ['PEPs']
@entity34186 :: (51056,Gene) :: ['PEPs']
